Method of diagnosing cancer based on MED15 and/or MED12

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides methods for diagnosing cancer, determining prognosis, and identifying new therapies using MED15 and/or MED12 as biomarkers. By measuring the expression levels or detecting mutations in these genes in patient samples, particularly for prostate cancers such as castration-resistant prostate cancer (CRPC), doctors can better diagnose the disease, predict outcomes, and find compounds that may effectively treat cancer by targeting these genes.

Use CasesContent extracted from patent full text and abstract with AI.

• Early detection and diagnosis of prostate cancer and its resistant forms using MED15 and/or MED12 as molecular markers.
• Stratification of patient risk and prognosis in prostate cancer, helping inform treatment decisions.
• Monitoring cancer progression or response to anti-androgen therapy by tracking MED15/MED12 levels.
• Screening and identifying new cancer treatment compounds that reduce the expression or activity of MED15 or MED12 in cancer cells.
• Development of targeted cancer therapies that inhibit MED15 and/or MED12 for the treatment of aggressive or resistant prostate cancers.
• Potential adaptation of methods for other cancer types exhibiting alterations in MED15 and/or MED12.

BenefitsContent extracted from patent full text and abstract with AI.

• Improves diagnostic accuracy for prostate cancer and its resistant forms, which may be undetectable by traditional PSA tests.
• Enables earlier intervention and more personalized treatment approaches by assessing individual risk and prognosis.
• Facilitates discovery of new targeted cancer therapies with higher effectiveness by focusing on validated molecular drivers of cancer proliferation.
• May reduce costs and increase frequency of testing since the methods can work with standard biological samples such as blood or tissue.
• Offers a prognostic tool that correlates with clinical outcomes, assisting in better management of high-risk cancer patients.
• Targets fundamental cancer mechanisms, potentially leading to treatments with broader applications or fewer side effects.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to methods of diagnosing cancer, determining the prognosis of a patient diagnosed with cancer and identifying a compound for treatment of cancer, using MED15 and/or MED12 as markers. In particular, the cancer is prostate cancer, castration-resistant prostate cancer (CRPC), distant metastatic CRPC or local recurrent CRPC. Furthermore, the invention relates to compounds for the treatment of cancer and use of MED15 and/or MED12 for diagnosis of cancer or prognosis of a patient suffering from cancer.